grant
Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence
Organization COLUMBIA UNIVERSITY HEALTH SCIENCESLocation NEW YORK, UNITED STATESPosted 1 Jul 2017Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY2026AbscissionAcuteAffectAfter CareAfter-TreatmentAftercareAnimal ModelAnimal Models and Related StudiesAstrocytesAstrocytusAstrogliaBody TissuesBrainBrain CancerBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCell BodyCell Communication and SignalingCell SignalingCellsChemoresistanceClinical TrialsComplexConvectionCyclicityCytotoxic agentCytotoxic drugDataDinucleoside PhosphatesDrug CombinationsDrug DeliveryDrug Delivery SystemsDrug ScreeningDrug TargetingDrugsEPEGEncephalonEposideEtoposideExcisionExtirpationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFundingGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHortega cellHumanHuman ResourcesHycamptamineHycamtamineIFNIMiDImmuneImmune Modulation TherapyImmune TargetingImmune mediated therapyImmune modulatory therapeuticImmunesImmunocompetentImmunologically Directed TherapyImmunotherapyIndividualInfiltrationInflammatoryInflammatory ResponseInterferonsIntracellular Communication and SignalingIntratumoral heterogeneityLastetMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMalignant Glial NeoplasmMalignant Glial TumorMalignant GliomaMalignant Neuroglial NeoplasmMalignant Neuroglial TumorMalignant Tumor of the BrainMalignant neoplasm of brainManpowerMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMesenchymalMiceMice MammalsMicrogliaModelingModern ManMolecularMolecular FingerprintingMolecular ProfilingMurineMusMyeloid CellsNMR ImagingNMR TomographyNatureNerve CellsNerve UnitNeural CellNeurocyteNeuroglial NeoplasmNeuroglial TumorNeuronsNuclear Magnetic Resonance ImagingOligodendrocytesOligodendrocytusOligodendrogliaOligodendroglia CellOperative ProceduresOperative Surgical ProceduresPDX modelPatient derived xenograftPatientsPeriodicityPharmaceutical PreparationsPhenotypePopulationPositionPositioning AttributeProductionProductivityPrognosisProliferatingRecurrenceRecurrentRecurrent NeoplasmRecurrent tumorRemovalReportingResearch SpecimenResectedRhythmicitySTING agonistsSamplingSignal TransductionSignal Transduction SystemsSignalingSliceSpecimenSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalTestingTimeTissuesTopoisomerase InhibitorsTopotecanTreatment EfficacyTumor CellTumor ImmunityVariantVariationVepesidZeugmatographyanti-tumor immune responseanti-tumor immunityantitumor immunityastrocytic gliabiological signal transductioncancer immunitycancer microenvironmentcancer progressioncell transformationcell typechemoresistantchemotherapychemotherapy resistancechemotherapy resistantcytokinedinucleotidedrug detectiondrug testingdrug/agentflow cytophotometrygitter cellglial-derived tumorglioblastoma multiformeheterogeneity in tumorsimmune competentimmune microenvironmentimmune modulating agentsimmune modulating drugimmune modulating therapeuticsimmune modulatory agentsimmune modulatory drugsimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmuno therapyimmunogenicimmunogenic apoptosisimmunogenic cell deathimmunomodulating agentsimmunomodulating drugsimmunomodulation therapyimmunomodulation treatmentimmunomodulator agentimmunomodulator drugimmunomodulator medicationimmunomodulator prodrugimmunomodulator therapeuticimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory agentsimmunomodulatory biologicsimmunomodulatory drugsimmunomodulatory therapeuticsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimprovedinhibitorintervention efficacyintra-tumoral heterogeneityintratumor heterogeneitymesogliamicroglial cellmicrogliocytemodel of animalmolecular phenotypemolecular profilemolecular signaturemouse modelmurine modelneoplasm progressionneoplasm recurrenceneoplasticneoplastic cellneoplastic progressionneuro-oncologyneuroglia neoplasmneuroglia tumorneuronalneurooncologynew approachesnew drug combinationnew pharmacotherapy combinationnovel approachesnovel drug combinationnovel pharmacotherapy combinationnovel strategiesnovel strategypatient derived xenograft modelperivascular glial cellpersonnelpost treatmentpreservationresectionresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell analysissingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingspongioblastoma multiformesuccesssurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapeutic immunomodulationtherapeutic immunoregulationtherapy efficacytooltransformed cellstumortumor heterogeneitytumor immune microenvironmenttumor microenvironmenttumor progressiontumor-immune system interactionstumors in the brain
Description preview
PROJECT SUMMARY
Glioblastoma (GBM) is a deadly form of malignant glioma against which conventional targeted therapies and
immunotherapies have had limited success. Both intratumoral heterogeneity and the complexities of drug
delivery in the brain are formidable challenges in neuro-oncology, while the “immune cold”…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click